SCHEMBL2938703

SCHEMBL2938703

NOC1C(O)[C@@H](CO)O[C@H]1n1cnc2c(O)nc(Cl)nc21

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.61
TP53 P04637 1/20 0.61
ADORA3 P0DMS8 4/20 0.59
ADORA1 P30542 4/20 0.59
ADORA2A P29274 4/20 0.59
PDE2A O00408 1/20 0.59
ADRA1A P35348 1/20 0.59
PDE4D Q08499 1/20 0.59
PDE3A Q14432 1/20 0.59
ADORA2B P29275 1/20 0.52
MEN1 O00255 1/20 0.52
CYP1A2 P05177 1/20 0.52
MAPK1 P28482 1/20 0.52
KMT2A Q03164 1/20 0.52
RXFP1 Q9HBX9 1/20 0.51
HTR2C P28335 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8904700 0.89 LMNA (0.61) LMNATP53ADORA3ADORA1ADORA2A
SCHEMBL8904692 0.89 LMNA (0.61) LMNATP53ADORA3ADORA1ADORA2A
SCHEMBL6560300 0.87 LMNA (0.80) LMNATP53ADORA3ADORA1ADORA2A
SCHEMBL6560285 0.87 LMNA (0.80) LMNATP53ADORA3ADORA1ADORA2A
SCHEMBL11311014 0.86 LMNA (0.65) LMNATP53ADORA3ADORA1ADORA2A
SCHEMBL11311032 0.86 LMNA (0.65) LMNATP53ADORA3ADORA1ADORA2A
SCHEMBL11311023 0.86 LMNA (0.65) LMNATP53ADORA3ADORA1ADORA2A
SCHEMBL7198801 0.80 ADORA3 (0.72) LMNATP53ADORA3ADORA1ADORA2A
SCHEMBL6399918 0.80 ADORA2A (0.76) LMNATP53ADORA3ADORA1ADORA2A
SCHEMBL3437027 0.80 ADORA3 (0.72) LMNATP53ADORA3ADORA1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside MITSUI CHEMICALS, INC. (JP) 2006-05-04 US claimed
US-20020193314-A1 Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside MITSUI CHEMICALS, INC. (JP) 2002-12-19 US claimed
EP-1178051-A2 PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2002-02-06 EP claimed
EP-1925675-B1 Process for production of nucleoside compound MITSUI CHEMICALS INC (JP) 2010-02-03 EP disclosed
EP-1338654-B1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND MITSUI CHEMICALS INC (JP) 2008-10-15 EP disclosed
EP-1925675-A1 Process for production of nucleoside compound Mitsui Chemicals, Inc. (JP) 2008-05-28 EP disclosed
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside MITSUI CHEMICALS, INC. (JP) 2006-05-04 US disclosed
US-7038039-B2 Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside MITSUI CHEMICALS, INC. (JP) 2006-05-02 US disclosed
EP-1179598-B1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND MITSUI CHEMICALS INC (JP) 2005-08-10 EP disclosed
US-20040219646-A1 Process for producing nucleoside compound MITSUI CHEMICALS, INC. (JP) 2004-11-04 US disclosed
CN-1476484-A Process for producing nucleoside compound 三井化学株式会社 2004-02-18 CN disclosed
EP-1338654-A1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND Mitsui Chemicals, Inc. (JP) 2003-08-27 EP disclosed
US-20020193314-A1 Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside MITSUI CHEMICALS, INC. (JP) 2002-12-19 US disclosed
EP-1179598-A1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND Mitsui Chemicals, Inc. (JP) 2002-02-13 EP disclosed
EP-1178051-A2 PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2002-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside PNP, MTAP, GALE LMNA 3037/4885TP53 3475/4885ADORA3 503/4885
US-20020193314-A1 Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside PNP, GALE, MTAP LMNA 3427/4885TP53 3433/4885ADORA3 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.